Africa Vaccine Market Size, Share & Trends Analysis Report By Technology (Recombinant & Conjugate Vaccines, Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Other), By Indication (Influenza, Polio, Rotavirus, Pneumococcal Disease, Human Papilloma Virus, Meningococcal Disease, Hepatitis, Varicella, Measles, Mumps, & Rubella, Diphtheria, Pertussis, & Tetanus (DPT), Other), By End-User (Pediatric, Adults, Travelers) Based on Region, And Segment Forecasts, 2021 - 2027

  • Report ID: BMRC 1707 | Number of pages: 194 | Published Date: Oct 2021

    Published | Category: Healthcare | Delivery Timeline: 48 hrs

COVID-19
To know the impact of COVID-19 On Africa Vaccine Market Size, Share & Trends Analysis Report By Technology (Recombinant & Conjugate Vaccines, Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Other), By Indication (Influenza, Polio, Rotavirus, Pneumococcal Disease, Human Papilloma Virus, Meningococcal Disease, Hepatitis, Varicella, Measles, Mumps, & Rubella, Diphtheria, Pertussis, & Tetanus (DPT), Other), By End-User (Pediatric, Adults, Travelers) Based on Region, And Segment Forecasts, 2021 - 2027 Market

Request Now
Market Size Forecast Scenarios (Optimistic, Baseline and Pessimistic) 2021-2027

Africa Vaccine Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2021-2027, Increasing feasibility of establishing sustainable vaccine manufacturing, rising government funding & support for new vaccine development and growing prevalence of infectious diseases Such as COVID-19, malaria & lassa fever are some of the major factors driving the growth of Africa Vaccine Market.

Africa Shows Significant Growth in Vaccine Market

Africa shows significant growth in vaccine market during the forecast period due to the rising COVID-19 cases and growing advancement in technology. For instance; in November 2020, Aspen's South African auxiliary Aspen Pharmacare has signed a fundamental deal with two Johnson and Johnson (J&J) auxiliaries for the technical exchange and proposed business manufacture of their COVID-19 vaccine applicant.

Scope of Africa Vaccine Market Report:

Africa vaccine market expected to show a significant growth in the coming few years. The prevalence of infectious diseases keeps on being excessively high in some African nations, with major effects on health and socio-economic. In 2014, Ebola flare-up in Western Africa has brought about strong proposals from the African Union and others with respect to help for the increase in speed of local vaccine development and manufacturing. Moreover, further developing reactions to emergency circumstances, African vaccine manufacturing could further develop security and supportability of vaccine supply, and react to neglect the health requirements of a developing populace and fast financial improvement in Africa. Efficient and secure vaccines against HIV and malaria can probably address approximately 13% of Africa's absolute infection trouble, and could on a very basic level shift Africa's vaccine market financially available. During the International Vaccine Technology Workshop in India, in September 2010, a group of intrigued Africans dispatched the African Vaccine Manufacturing Initiative (AVMI). Looking past, the arrangement of vaccines in emergency circumstances, the AVMI expects to organize efforts of African vaccine makers and other invested individuals, who have a dream to see Africa produce its own vaccines and biologicals for both daily schedule and emergency circumstances.

The COVID-19 pandemic has also impacted the growth of Africa vaccine market. During COVID-19 pandemic, the South African Medical Research Council has been enthusiastically subsidizing, leading and working on research and development activities to develop vaccine. Increasing investment  by government and private organizations for the development of COVID-19 vaccines has further accelerated the market in the Africa. However, during COVID-19 pandemic, because of transportation restrictions and lockdown conditions there is supply chain disruption of raw material.

Africa Vaccine Market Segmentation:

Global Africa vaccine market report is segmented on the basis of by technology, indication, end-user and region & country level. Based upon technology, Africa vaccine market is classified into recombinant & conjugate vaccines, inactivated vaccines, live attenuated vaccines, and toxoid vaccines and other. Based upon indication, the market is divided into influenza, polio, rotavirus, pneumococcal disease, human Papilloma virus, meningococcal disease, hepatitis, Varicella, measles, mumps, & rubella, diphtheria, Pertussis, & tetanus (DPT) and other. Based upon end-user, Africa vaccine market is classified into pediatric, adults and travelers.

By Technology:

  • Recombinant & Conjugate Vaccines
  • Inactivated Vaccines
  • Live Attenuated Vaccines
  • Toxoid Vaccines
  • Other

By Indication:

  • Influenza
  • Polio
  • Rotavirus
  • Pneumococcal Disease
  • Human Papilloma Virus
  • Meningococcal Disease
  • Hepatitis
  • Varicella, Measles, Mumps, & Rubella
  • Diphtheria, Pertussis, & Tetanus (DPT)
  • Other

By End-User:

  • Pediatric
  • Adults
  • Travelers

Key Players of Africa Vaccine Market Report

Some of the key players for Africa vaccine market are Institut Pasteur Dakar,  Institut Pasteur de Tunis, Moderna Inc., Vacsera, Biovac, Ethiopian Public Health Institute (EPHI), Biovaccines Nigeria Limited (BVNL), Innovative Biotech, and others.

News: Moderna Plans to Spend $500 Million on Vaccine Plant in Africa

October 7th, 2021; Moderna wanted to build a vaccine producing facility in Africa. It would spend as much as $500 million to construct a plant in Africa that could create a large portion of a billion messenger RNA vaccine dosages a year. They incorporate its Covid-19 vaccine and shots for different diseases, and possibly likewise have vial-filling abilities. The other primary producers of mRNA vaccines for Covid-19, Pfizer Inc. also, accomplice BioNTech SE, declared an arrangement in July to begin creating shots at an office in Cape Town, South Africa. The new "cutting edge" office would ultimately deliver up to 500 million portions per year of Moderna's mRNA vaccine, which has shown a efficacy rate of in excess of 90% in avoiding Covid-19.

New consortium working to boost vaccine production in South Africa

On July 30th, 2021; The Medicines Patent Pool (MPP) and the World Health Organization (WHO),  Afrigen Biologics (PTY) Limited, the Biologicals and Vaccines Institute of Southern Africa  (Biovac), the South African Medical Research Council (SAMRC) and Africa Centres for Disease Control and Prevention (Africa CDC) have signed a letter of intent to address the global imbalance of manufacturing capacity for COVID-19 vaccines. This letter of intent brings together partners to establish the South African mRNA technology transfer hub that will allow for greater and more diversified vaccines manufacturing capability, strengthen African regional health security and respond more equitably to the current COVID-19 pandemic and future pandemics. Further to WHO's announcement in June of the first COVID mRNA vaccine technology transfer hub in South Africa, this letter of intent sets out the terms of the collaboration and responsibilities between our organizations. The new collaboration brings together key actors from COVAX partners, industry, government, academia, funding agencies, WHO AFRO, which was represented by Regional Director Dr. Matshidiso Moeti and the Africa CDC to collectively provide an enabling environment for the development of the first regional mRNA vaccine manufacturing production facility in Africa.

Increasing Feasibility of Establishing Sustainable Vaccine Manufacturing, Rising Government Funding & Support for New Vaccine Development and Growing Prevalence of Infectious Diseases Such as COVID-19, Malaria & Lassa Fever are Some of the major factors Driving the Market Growth

One of the major factors driving the growth of Africa vaccine market is increasing feasibility of establishing sustainable vaccine manufacturing. Vaccination addresses one of the most cost-effective general health mediations. The requests for next-generation and new vaccines are consistently developing. Vaccination stays the most cost-effective general health intercession after clean water, and the advantages impressively offset the expenses. The efforts expected to satisfy the consistently developing demands for future and novel vaccines intended for arising microorganisms and new signs are just feasible in a sustainable business model. For instance; in November 2020, FCDO created far reaching reality base on vaccine manufacturing in Africa. Also, in April 2021, the African Union proclaimed its aim to speed up nearby vaccine production to meet 60% of Africa's normal immunization needs by 2040.

In addition, increasing government funding & support for new vaccine development is also supplementing the market growth in Africa. Vaccination is one of the main medical practices at any point presented, it has been fundamental to diminish mortality, further develop future and financial development. Government in Africa, have shown interest in vaccine production foundations however just with outer help for investment. For instance; Ethiopia spends USD 150 Million yearly on immunization obtainment of which USD 100 Million presently come from contributors. Eventually, upon graduation, the Ethiopian government is relied upon to significantly increase its financial plan distributed to vaccine importation to support its vaccination program.

Furthermore, growing prevalence of infectious diseases such as COVID-19, malaria & Lassa fever also fostering the Africa vaccine market growth. Africa has the maximum occurrence of mortality caused by infectious diseases like COVID-19, malaria and Lassa fever. Rapidly growing COVID-19 cases increasing the vaccine demand in Africa. For example; according to the World Health Organization (WHO), there are about 2,909,757 COVID-19 cases and 88,104 deaths in South Africa, in October 2021. However, shortage of enabling ecosystem and lack of existing support will raise indirect cost and create challenge to probability for production in Africa. In spite of that, advancement in life science and biomedical technologies can provide various opportunities for the further growth of the Africa vaccine market.

Key Benefits of Africa Vaccine Market Report

  • Africa Vaccine Market report covers in-depth historical and forecast analysis.
  • Africa Vaccine Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, Regional and Country Level.
  • Africa Vaccine Market report helps to identify opportunities in marketplace.
  • Africa Vaccine Market report covers extensive analysis of emerging trends and competitive landscape.

 


Interested in this report?

Africa Vaccine Market Share Industry Size, Trends, Growth Analysis to 2021-2027 and Analysis 2019-2025

report cover

Request for Table of Content

Africa Vaccine Market Size, Share & Trends Analysis Report By Technology (Recombinant & Conjugate Vaccines, Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Other), By Indication (Influenza, Polio, Rotavirus, Pneumococcal Disease, Human Papilloma Virus, Meningococcal Disease, Hepatitis, Varicella, Measles, Mumps, & Rubella, Diphtheria, Pertussis, & Tetanus (DPT), Other), By End-User (Pediatric, Adults, Travelers) Based on Region, And Segment Forecasts, 2021 - 2027

Note: For delivery of sample pages you must have a Domain Specific Email ID, normally your business email address complies. Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSNetc. are not accepted.
Brandessence market research actively tracks, monitors, and analyses key industry trends in real-time via B2B surveys in 60 + countries and territories.

    Pricing


Looking for Regional Reports?